Integrating metastasectomy and stereotactic radiosurgery in the treatment of metastatic renal cell carcinoma

Bex, Axel

doi:10.1016/j.ejcsup.2013.07.017

Cited by 4 publications

(2 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although multivariate analysis was performed to account for confounding factors in the systematic reviews and some of the primary series, the possibility of unseen confounders limits the strength of the conclusions that can be drawn regarding the benefit of surgery. The association between metastasectomy and longer OS could be explained by unmeasured enrichment for favorable disease biology or host characteristics in patients selected by their physicians for surgery [27].…”

Section: Discussionmentioning

confidence: 99%

“…Some of these excluded variables, such as tumor size and MSKCC or IMDC risk score, were associated with survival in individual studies. In general, solitary or oligometastatic disease, metachronous metastasis with a disease-free interval of >2 years, complete resection, and absence of lymph node involvement are associated with favorable outcome after metastasectomy [27,28].…”

Section: Prognostic Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review

Achkar

Maranchie

Appleman

2019

KCA

View full text Add to dashboard Cite

Introduction: Metastasectomy for advanced renal cell carcinoma has been practiced for over 80 years. However, there is uncertainty regarding the clinical benefit of this procedure and the optimum selection of appropriate patients. Materials and Methods: A systematic literature search was conducted according to the PRISMA statement to identify studies that reported outcomes in patients who underwent metastasectomy at any time. Primary endpoints were overall and disease-free survival. Radiation therapy studies were not included. Case reports and series with less than 20 patients were not included. Results: Forty-four studies were identified that met the criteria for inclusion, with a total of 4195 patients. No studies that randomized patients to surgery versus no surgery were identified. Disease-free interval, number of metastatic sites and completeness of resection were prognostic for overall survival in many of the included studies. Seventeen studies included patients with lung metastases only (1465 patients in total). Conclusions: Case series have documented patients with prolonged disease-free interval and survival after metastasectomy. However, without randomized data, the impact of metastasectomy on outcomes in patients with metastatic renal cell carcinoma (mRCC) remains unknown, especially in the evolving landscape of systemic therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Prognostic Factorsmentioning

confidence: 99%